Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $310.10 and traded as high as $316.86. Krystal Biotech shares last traded at $315.34, with a volume of 345,860 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the company. Weiss Ratings lowered Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a research report on Wednesday, November 4th. TD Cowen cut their price target on shares of Krystal Biotech from $403.00 to $380.00 and set a "buy" rating on the stock in a research report on Tuesday, November 3rd. Bank of America increased their price objective on Krystal Biotech from $392.00 to $400.00 and gave the company a "buy" rating in a report on Monday, September 21st. The Goldman Sachs Group started coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They issued a "buy" rating and a $441.00 target price for the company. Finally, William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a research report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of "Moderate Buy" and a consensus price target of $375.00.
Check Out Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Price Performance
The business's 50-day moving average is $323.84 and its 200 day moving average is $310.10. The firm has a market capitalization of $9.34 billion, a P/E ratio of 42.79 and a beta of 0.56.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.26. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. The firm had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. Analysts anticipate that Krystal Biotech, Inc. will post 7.74 EPS for the current fiscal year.
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Krystal Biotech in the second quarter valued at approximately $1,554,113,000. Soleus Capital Management L.P. raised its position in Krystal Biotech by 21.3% during the third quarter. Soleus Capital Management L.P. now owns 1,139,700 shares of the company's stock valued at $379,019,000 after purchasing an additional 200,446 shares in the last quarter. William Blair Investment Management LLC bought a new stake in Krystal Biotech during the second quarter worth $211,909,000. Goldman Sachs Group Inc. lifted its stake in Krystal Biotech by 43.8% during the third quarter. Goldman Sachs Group Inc. now owns 429,739 shares of the company's stock worth $142,914,000 after purchasing an additional 130,898 shares during the last quarter. Finally, Jupiter Topco LLC bought a new stake in Krystal Biotech during the second quarter worth $95,387,000. Institutional investors own 86.29% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients' cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin's structure.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.